KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Taxes (2021 - 2024)

Moderna (MRNA) has disclosed Change in Taxes for 4 consecutive years, with -$2.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Change in Taxes fell 122.22% to -$2.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$51.0 million, a 410.0% decrease, with the full-year FY2023 number at $15.0 million, up 101.81% from a year prior.
  • Change in Taxes was -$2.0 million for Q3 2024 at Moderna, up from -$45.0 million in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $716.0 million in Q1 2022 to a low of -$1.2 billion in Q2 2022.
  • A 4-year average of $333333.3 and a median of $7.0 million in 2023 define the central range for Change in Taxes.
  • Biggest YoY gain for Change in Taxes was 695.56% in 2022; the steepest drop was 533.1% in 2022.
  • Moderna's Change in Taxes stood at $311.0 million in 2021, then crashed by 105.79% to -$18.0 million in 2022, then soared by 138.89% to $7.0 million in 2023, then plummeted by 128.57% to -$2.0 million in 2024.
  • Per Business Quant, the three most recent readings for MRNA's Change in Taxes are -$2.0 million (Q3 2024), -$45.0 million (Q2 2024), and -$11.0 million (Q1 2024).